Purple Biotech ( (PPBT) ) has shared an announcement.
On April 28, 2025, Purple Biotech announced positive data from their NT219 study presented at the AACR Annual Meeting, highlighting its potential in treating colorectal and head and neck cancers. The data suggests NT219’s ability to restore immunotherapy efficacy and expand patient eligibility, with biomarkers identified for patient response prediction. This advancement strengthens Purple Biotech’s position in oncology, potentially benefiting stakeholders by enhancing treatment options for resistant cancers.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer mechanisms and pathways. The company is headquartered in Rehovot, Israel.
YTD Price Performance: -41.18%
Average Trading Volume: 16,432
Technical Sentiment Signal: Hold
Current Market Cap: $7.17M
For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.